WO2007086457A1 - 乾式直打速崩壊性錠剤 - Google Patents

乾式直打速崩壊性錠剤 Download PDF

Info

Publication number
WO2007086457A1
WO2007086457A1 PCT/JP2007/051156 JP2007051156W WO2007086457A1 WO 2007086457 A1 WO2007086457 A1 WO 2007086457A1 JP 2007051156 W JP2007051156 W JP 2007051156W WO 2007086457 A1 WO2007086457 A1 WO 2007086457A1
Authority
WO
WIPO (PCT)
Prior art keywords
sodium
disintegrating tablet
dry
acid
tablet
Prior art date
Application number
PCT/JP2007/051156
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
Misa Tateda
Satoshi Sakuma
Itsumi Enomoto
Original Assignee
Toa Pharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toa Pharmaceuticals Co., Ltd. filed Critical Toa Pharmaceuticals Co., Ltd.
Priority to CN200780003393XA priority Critical patent/CN101374503B/zh
Priority to KR1020087019484A priority patent/KR101386022B1/ko
Publication of WO2007086457A1 publication Critical patent/WO2007086457A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to a dry-type direct-disintegrating tablet having a practical tablet hardness while maintaining fast disintegration by devising a combination of an active ingredient and a compounding ingredient, and a method for producing the same. .
  • Tablets as fast-disintegrating tablets in the oral cavity include (1) disintegration within 30 seconds according to the disintegration test method of the Japanese Pharmacopoeia, (2) disintegration property of disintegrating within 60 seconds in the oral cavity, ( 3) Wornness test Hardness, etc., that no noticeable damage is observed at 200 revolutions, is required.
  • a wet granulation method and a dry granulation method have been proposed as methods for producing such an intraorally rapidly disintegrating tablet.
  • the wet granulation method for example, the surface of the saccharide particles is moistened with 0.3 to 7% by weight of water to a tablet component containing (1) a medicinal ingredient and a saccharide as an excipient.
  • the disintegration time according to the disintegration test method described in the Japanese Pharmacopoeia 12th Amendment by compressing the mixture containing the medicinal ingredient, saccharide and water and then drying is 0.05 to 3.0 minutes.
  • Patent Document 1 A method for producing an orally disintegrating tablet (Patent Document 1) has been reported.
  • the mixture containing the excipient is selected from at least one disintegrant and starch, modified starch, or microcrystalline cellulose, and at least one swelling agent that does not produce high viscosity when contacted with water, or It contains at least one solubilizing agent, and tablets do not contain effervescent agents and free organic acids, and rapidly disintegrate in the oral cavity in the presence of saliva and in less than 60 seconds without chewing. It is a particle tablet.
  • composition by a dry granulation method for example, (3) Meloxicam as an active ingredient; Oligosaccharide and / or polysaccharide; Surfactant, hydrotropic agent, alcoholic agent, no, id mouth Proposed pharmaceutical composition (Patent Document 3) comprising one or more pharmaceutically acceptable additives selected from the group consisting of colloids and polymers; and any excipients, carriers and / or auxiliaries It has been done.
  • Orally disintegrating composition (Patent Document 4), or (5) meloxicam or a pharmaceutically acceptable salt, starch or various types of starch, a glidant and at least one additional excipient
  • a direct dry press method direct compression method
  • meloxicam meloxicam, ratatose, starch and silicon dioxide water
  • a Japanese blend is prepared by mixing the ingredients in a conventional mixer for 30 minutes, then adding magnesium stearate and adding 5 more of the composition. Method of blending between (Patent Document 5) have been reported.
  • Patent Document 1 Japanese Patent No. 3069458
  • Patent Document 2 Japanese Patent No. 2820319
  • Patent Document 3 Japanese Patent Publication No. 2001-513563
  • Patent Document 4 Japanese Patent Laid-Open No. 2000-273039
  • Patent Literature 5 Special Table 2004-525975
  • the dry tableting method is a method in which after mixing a drug and other excipients, the mixture is directly tableted (direct compression method) to form a tablet.
  • This is a simple preparation method.
  • the fluidity of the mixture will be low, so that the powder mixture will not flow out of the hopper of the tableting machine, and it will be impossible to compress the tablet, It was observed that the rate declined and the tablet weight deviation significantly increased, or that the tablet hardness could not be maintained if the tablet disintegration was improved.
  • the present invention relates to a caving that improves the flowability of the mixed powder before tableting by devising the combination of the active ingredient and the compounding ingredient, and therefore has good spillability from the hopper of the tableting machine.
  • a rapidly disintegrating tablet having a practical tablet hardness while maintaining the disintegration of the tablet with a small tablet weight deviation and a production method by the dry direct compression method The purpose is to provide.
  • the present invention can select meloxicam which is a non-steroidal anti-inflammatory / analgesic agent as an active ingredient and provide an effective fast disintegrating tablet containing meloxicam.
  • the present invention has, as its basic aspect, (a) an active ingredient and (b) a solubilizing agent.
  • An acid selected from citrate, tartaric acid, malic acid, lactic acid and ascorbic acid or an alkali metal salt thereof; an alkali metal bicarbonate; and at least one selected from the group consisting of alkali metal carbonates, and
  • c Contains lubricants consisting of a combination of magnesium stearate and sucrose fatty acid ester as excipients), (d) binders, (e) disintegrants, (f) glidants, and (g) lubricants. It is a dry-type direct hitting disintegrating tablet characterized by the above.
  • the present invention relates to alkali metal salt strength of acids sodium citrate, potassium citrate, sodium tartrate, potassium tartrate, sodium malate, potassium malate, sodium lactate, potassium lactate, ascorbic acid
  • a dry direct-disintegrating tablet that is sodium or potassium ascorbate the alkali metal bicarbonate is sodium bicarbonate or potassium bicarbonate, and the alkali metal carbonate is sodium carbonate or potassium carbonate.
  • the solubilizing agent (b) is a combination of both sodium citrate and sodium bicarbonate
  • the excipient (c) is Group consisting of sugar, lactose, erythritol, D-mannitol, xylitol, maltitol, etc., synthetic quinoleminium, hydroxypropyl starch sodium, crystalline cellulose, hydroxypropinole starch, anhydrous calcium hydrogen phosphate, reduced maltose water solution It is a dry direct-disintegrating tablet that is one or more types selected from.
  • the binder in (d) is at least one selected from the group consisting of crystalline cellulose, powdered cellulose, low-substituted hydroxypropylcellulose, and carmellose
  • the fluidizing agent (f) is light anhydrous caustic acid (silicon dioxide). It is a quick-disintegrating tablet.
  • the present invention relates to a dry-type direct-disintegrating tablet in which the active ingredient (a) is meloxicam, and specifically includes the following components:
  • the solubilizing agent is sodium citrate and sodium bicarbonate
  • the excipient is lactose and erythritol
  • the binder of (d) is crystalline cellulose
  • (e) disintegrant is crospovidone
  • fluidizing agent is light anhydrous caustic anhydride (silicon dioxide),
  • (g) lubricant is magnesium stearate and sucrose fatty acid ester
  • the present invention provides, as another aspect, (a) meloxicam, (b) sodium taenoate and sodium bicarbonate as a solubilizer, (c) an excipient, (d) a binder, (e) Disintegrating agent and (f) fluidizing agent are mixed, and (g) magnesium stearate and sucrose fatty acid ester are added and mixed as a lubricant, and then the resulting mixture is directly compressed into tablets.
  • meloxicam sodium taenoate and sodium bicarbonate as a solubilizer
  • an excipient e
  • a binder e
  • Disintegrating agent and (f) fluidizing agent are mixed, and (g) magnesium stearate and sucrose fatty acid ester are added and mixed as a lubricant, and then the resulting mixture is directly compressed into tablets.
  • the present invention provides an acid selected from citrate, tartaric acid, malic acid, lactic acid and ascorbic acid or an alkali metal salt thereof as a solubilizing agent to be blended in addition to the active ingredient Z excipient and the like.
  • a lubricant comprising at least one selected from the group consisting of alkali metal bicarbonates; and alkali metal carbonates, and further comprising a combination of both magnesium stearate and sucrose fatty acid ester as lubricants Therefore, a dry-type quick-disintegrating tablet having a desired rapid disintegration property and appropriate hardness is provided.
  • the flowability of the mixed powder containing the active ingredient before tableting is good, and therefore, the occurrence of cabbing with good flowability of the mixed powder from the hopper of the tableting machine is suppressed, and as a result
  • a rapidly disintegrating tablet having almost no tablet weight deviation and a method for producing the tablet by the dry direct compression method are provided.
  • the fast disintegrating tablet obtained by the present invention has a desired disintegration rate and a practical tablet hardness, and its manufacturing method has the advantage of being an inexpensive and simple manufacturing method. Have.
  • the medicinal ingredients used in the dry direct-disintegrating tablet of the present invention are not particularly limited, for example, non-steroidal antipyretic analgesic / anti-inflammatory agents, vitamins, antihistamines, antitussives, fungicides, antacids, Herbal medicine, gastric mucosa repair agent, analgesic antispasmodic agent, constipation treatment agent, H2 receptor antagonist, Examples include ulcer treatment agents, antihypertensive agents, antibiotics, arrhythmia treatment agents, gastrointestinal drugs, expectorants, antipruritic drugs (vehicle sickness drugs), and central nervous stimulants.
  • non-steroidal antipyretic analgesic / anti-inflammatory agents can be preferably applied.
  • Meloxicam is a pale yellow powder that is extremely insoluble in methanol and ethanol, is almost insoluble in water, and has a melting point of 241 ° C. It is also a non-steroidal anti-inflammatory agent with no bitterness, as a rheumatoid arthritis, osteoarthritis, low back pain, shoulder periarthritis, scapulohumeral disease group disease and anti-inflammatory analgesic, as a tablet containing lOmg Oral administration once a day after meals.
  • an average particle size of 20 ⁇ or less is used.
  • Examples of the solubilizing agent used together with the above active ingredients include acids or alkali metal salts, alkali metal hydrogen carbonates or alkali metal carbonates thereof.
  • such acids are selected from the group consisting of citrate, tartaric acid, malic acid, lactic acid, and ascorbic acid. Therefore, as alkali metal salts of acids, Examples thereof include sodium acid, potassium citrate, sodium tartrate, potassium tartrate, sodium malate, potassium malate, sodium lactate, potassium lactate, sodium ascorbate, and potassium ascorbate.
  • examples of the alkali metal hydrogen carbonate as the solubilizing agent include sodium hydrogen carbonate or potassium hydrogen carbonate, and examples of the alkali metal carbonate include sodium carbonate or potassium carbonate.
  • solubilizing agents can be used in combination of one or more.
  • a combination of both sodium citrate and sodium bicarbonate is particularly preferred.
  • the blending amount of the solubilizing agent in the present invention is the active ingredient used, the type of solubilizing agent, etc.
  • the blending amount of the solubilizing agent is expressed in terms of% by weight, the total amount of sodium quenate and sodium bicarbonate is preferably about 0.5 to 6% by weight per tablet.
  • the most preferable mixing ratio of sodium citrate and sodium hydrogen carbonate is as follows.
  • Sodium hydride 0.3 to 1.9 monole, preferably 0.57 to 1.72 monole, more preferably f 0.7 to 1.6 monole.
  • the amount of sodium citrate and sodium hydrogencarbonate to be blended by the combination based on the above molar ratio is such that when one tablet is dissolved in 900 mL of distilled water, the pH of the solution is 4-8. Combine them so that they are between 5. More preferably, the pH ranges from pH 5.0 to 8.0, and particularly preferably pH 6.5 to 7.5.
  • the preferred blending amounts of the respective components as the solubilizing agent are the same as described above.
  • the pH of the solution is 4 to 8.5, preferably 5 ⁇ 0 to 8 ⁇ 0, particularly preferably pti 6.5 to 5 ⁇ 7.5.
  • excipients include lactose, erythritol, D-mannitol, xylitol, maltitol and other sugars, synthetic aluminum silicate, hydroxypropyl starch sodium, crystalline cellulose , Hydroxypropyl starch, water-free calcium hydrogen phosphate, reduced maltose starch and the like.
  • lactose and erythritol which can be used as a flavoring agent are preferably used.
  • the blending amount of the excipient to be blended per tablet is 20 to 70% by weight, preferably 30 to 70% by weight, and more preferably about 60% by weight.
  • crystalline cellulose powder examples thereof include powdered cellulose, low-substituted hydroxypropylcellulose, and carmellose.
  • crystalline cellulose for example, CELUS PH101, CELUS PH302 [manufactured by Asahi Kasei Chemicals Corporation].
  • the amount of binder used per tablet is 5 to 20% by weight, preferably about 10% by weight.
  • examples of the disintegrant include one or more selected from the group consisting of crospovidone, carmellose, carmellose calcium, and sodium carboxymethyl starch.
  • crospovidone is used.
  • the amount of disintegrant added per tablet is 5 to 20% by weight, preferably about 15% by weight.
  • Examples of the fluidizing agent include light anhydrous silicic acid (silicon dioxide) strength S.
  • Ad Solida 101 [trade name, manufactured by Freund Sangyo Co., Ltd.] can be used.
  • the blending amount of the fluidizing agent per tablet is 0.5 to 3% by weight, preferably about 0.5 to 1.5% by weight.
  • the fast disintegrating tablet provided by the present invention is characterized in that both magnesium stearate and sucrose fatty acid ester are used in combination as lubricants.
  • sucrose fatty acid ester include sugar ester B-370F, or Surf Hope J 2 203F [Sucrose behenic acid ester used as lubricant for B-370; Mitsubishi Chemical Foods, Inc. ) Made] and the like.
  • the blending ratio of magnesium stearate and sucrose fatty acid ester is about 1 :: ⁇ 2 in weight ratio, preferably about 1: 1 ⁇ !
  • the blending amount per tablet as the total amount of the lubricant is 1.0 to 3% by weight, preferably about 1.0 to 2.0% by weight.
  • a masking agent for masking strong bitterness can be blended according to a conventional method.
  • a masking agent include sweeteners such as aspartame and tautiman, and fragrances such as les or 1_menthol, dry coat cocoon, brown sugar flavor, dry coat peppermint, and grapefruit coat.
  • sweeteners such as aspartame and tautiman
  • fragrances such as les or 1_menthol, dry coat cocoon, brown sugar flavor, dry coat peppermint, and grapefruit coat.
  • the amount of these masking agents can be increased or decreased as appropriate depending on the active ingredient to be included. The power to do S.
  • the dry direct hit disintegrating tablet provided by the present invention can be prepared, for example, by a manufacturing method according to the following steps.
  • This method is generally composed of two steps: a first step of mixing each component constituting the tablet, and then a second step of tableting.
  • Each step itself is simple and efficient that can be performed according to a conventional method. It is a preparation method of a tablet.
  • a predetermined amount of the following components (a) an active ingredient, (b) a solubilizer, (c) an excipient, (d) a binder, (e) a disintegrant, and (f) a fluidizing agent are usually added.
  • a mixer trade name, Bore container mixer; manufactured by Kotopuki Giken Kogyo Co., Ltd.].
  • the mixing time at this time varies depending on the type of additive to be used, the amount used, etc., and is not particularly limited, but is preferably 5 to 40 minutes, more preferably 5 to 30 minutes.
  • the mixing time at this time is not particularly limited depending on the amount of the mixture used as long as the lubricant can be sufficiently mixed, but usually 2 to 10 minutes, preferably 2 to 4 minutes.
  • a taste-masking agent such as erythritol may be added if desired.
  • direct dry tableting can be used to prepare the intended dry direct compression fast disintegrating tablet of the present invention.
  • the perfume used in the fast disintegrating tablet provided by the present invention is a force that can be added in either the first step or the second step, preferably in the second step.
  • the sweetener used in the tablet of the present invention can be applied with any of the first step or the second step.
  • meloxicam having each particle size is prepared and used.
  • each component was mixed and tableted to obtain a dry-type direct-disintegrating tablet.
  • (a) is the active ingredient
  • (b) is a solubilizer
  • (c) is an excipient
  • (d) is a binder
  • (e) is a disintegrant
  • (f) is fluidized.
  • (G) is a lubricant
  • (h) is a corrigent
  • (i) is a sweetener
  • ( j) is a fragrance.
  • Example 1 A typical production operation example is shown in the formulation of Example 1.
  • the obtained mixture was directly tableted to obtain a tablet weighing 375 mg containing 15 mg of the active ingredient.
  • each tablet was prepared according to the above. However, in Examples 8 and 9, the tablets are 250 mg in weight containing 10 mg of the active ingredient.
  • a tablet containing 15 mg of active ingredient (total weight: 375 mg) was prepared in the same manner as in the production method of Example 7, except that 4 parts by weight of meloxicam and sodium citrate was used, and 1 part by weight of sodium bicarbonate. did.
  • a tablet containing 15 mg of the active ingredient (total weight: 375 mg) was prepared in the same manner as in the production method of Example 7, except that 3 parts by weight of meloxicam and sodium citrate was used, and 2 parts by weight of sodium bicarbonate. did.
  • Example 3 In the tablet preparation method of Example 3, the mixture obtained in the same manner except that brown sugar flavor (0.2 g) or dry coat peppermint (0.2 g) was added as a fragrance was effective by tableting. A tablet containing 15 mg of the ingredient (total weight: 375 mg) was prepared. The characteristics such as dissolution behavior of these tablets were not different from those of Example 3, and the taste of these tablets was good.
  • each component was mixed and tableted to obtain a dry-type direct hitting collapsible tablet.
  • Particle size m 60-80 60-80 80 60-80 60-80 7-15 7-15
  • Comparative Examples 1 to 4 use meloxicam having an average particle size of 60 to 80 ⁇ m, and in Comparative Example 1, only sodium bicarbonate was added in an amount of 0.25 parts by weight to 1 part by weight of meloxicam. Comparative Examples 1 to 4 are tablets obtained by adding 1, 2.5 and 5 parts by weight, respectively, of 1 part by weight of meloxicam to sodium quenate.
  • Tableting was performed using magnesium stearate or sucrose fatty acid ester alone as a lubricant, but cabbing occurred, yield decreased, and was not practical.
  • the tablets of Examples:! To 9 use meloxicam having an average particle size of 4 to 15 ⁇ m, and both sodium citrate and sodium bicarbonate are used as a solubilizer. Since the desired dissolution behavior can be obtained thereby, the specific force of the present invention is well understood.
  • the present invention provides a dry-type direct-disintegrating tablet having a practical tablet hardness while maintaining rapid disintegration, particularly a direct-disintegrating tablet containing meloxicam. Since the dissolution behavior is also good, the medical value is tremendous.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2007/051156 2006-01-26 2007-01-25 乾式直打速崩壊性錠剤 WO2007086457A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN200780003393XA CN101374503B (zh) 2006-01-26 2007-01-25 干式直压速崩性片剂
KR1020087019484A KR101386022B1 (ko) 2006-01-26 2007-01-25 건식 직타 속붕괴성 정제

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-017401 2006-01-26
JP2006017401A JP4965130B2 (ja) 2006-01-26 2006-01-26 乾式直打速崩壊性錠剤

Publications (1)

Publication Number Publication Date
WO2007086457A1 true WO2007086457A1 (ja) 2007-08-02

Family

ID=38309245

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/051156 WO2007086457A1 (ja) 2006-01-26 2007-01-25 乾式直打速崩壊性錠剤

Country Status (4)

Country Link
JP (1) JP4965130B2 (enrdf_load_stackoverflow)
KR (1) KR101386022B1 (enrdf_load_stackoverflow)
CN (1) CN101374503B (enrdf_load_stackoverflow)
WO (1) WO2007086457A1 (enrdf_load_stackoverflow)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020262618A1 (en) * 2019-06-28 2020-12-30 Ssp Co., Ltd. Meloxicam-containing granulated product
CN115093859A (zh) * 2022-05-05 2022-09-23 朱贵远 一种聚丙烯酸钠防溅制剂及其制备方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
WO2010041441A1 (ja) 2008-10-08 2010-04-15 独立行政法人 農業環境技術研究所 有害物質吸着成形体
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
JP5810819B2 (ja) * 2011-10-14 2015-11-11 ライオン株式会社 積層錠
JP5945191B2 (ja) * 2012-08-09 2016-07-05 株式会社ファンケル 口腔内速崩錠
JP6092672B2 (ja) * 2013-03-21 2017-03-08 株式会社ファンケル 口腔内速崩壊性錠剤
JP6266891B2 (ja) * 2013-03-29 2018-01-24 株式会社ロッテ 口腔内洗浄用組成物
CN103417512B (zh) * 2013-08-20 2015-08-12 吉林显锋科技制药有限公司 一种阿莫西林胶囊剂及其制备方法
US11786471B2 (en) * 2016-07-11 2023-10-17 Wuhan Ll Science And Technology Development Co. Ltd. Complex disintegrant system for oral solid preparation and oral solid preparation comprising said complex disintegrant system
CN107970219A (zh) * 2017-12-27 2018-05-01 佛山市南海东方澳龙制药有限公司 宠物用美洛昔康片及其制备方法和应用
JP2023019148A (ja) * 2021-07-28 2023-02-09 エスエス製薬株式会社 一般用医薬品
JP2023019149A (ja) * 2021-07-28 2023-02-09 エスエス製薬株式会社 錠剤

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054752A1 (fr) * 1999-03-15 2000-09-21 Kaken Pharmaceutical Co., Ltd. Comprimes a delitement rapide et procede de fabrication
JP2000273039A (ja) * 1999-01-20 2000-10-03 Taisho Pharmaceut Co Ltd 口腔内崩壊性組成物
JP2001513563A (ja) * 1997-08-27 2001-09-04 ヘキサル アーゲー 溶解性および生物学的利用能の改良されたメロキシカムの医薬組成物
JP2004525975A (ja) * 2001-04-21 2004-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 素早く崩壊するメロキシカム錠剤
WO2004071490A1 (en) * 2003-02-12 2004-08-26 R & P Korea Co., Ltd. Solvent system of hardly soluble drug with improved elution rate
WO2005123040A1 (ja) * 2004-06-22 2005-12-29 Shionogi & Co., Ltd. 口腔内速崩壊錠

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513561A (ja) * 1997-08-27 2001-09-04 メルク エンド カムパニー インコーポレーテッド プレニル蛋白トランスフェラーゼ阻害薬
JP3435664B2 (ja) * 1999-12-08 2003-08-11 ヤンセンファーマ株式会社 口腔内速崩壊型錠剤及びその製造方法
JP2005306770A (ja) * 2004-04-21 2005-11-04 Toa Eiyo Ltd 口腔内速崩壊型製剤及びその製造方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513563A (ja) * 1997-08-27 2001-09-04 ヘキサル アーゲー 溶解性および生物学的利用能の改良されたメロキシカムの医薬組成物
JP2000273039A (ja) * 1999-01-20 2000-10-03 Taisho Pharmaceut Co Ltd 口腔内崩壊性組成物
WO2000054752A1 (fr) * 1999-03-15 2000-09-21 Kaken Pharmaceutical Co., Ltd. Comprimes a delitement rapide et procede de fabrication
JP2004525975A (ja) * 2001-04-21 2004-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 素早く崩壊するメロキシカム錠剤
WO2004071490A1 (en) * 2003-02-12 2004-08-26 R & P Korea Co., Ltd. Solvent system of hardly soluble drug with improved elution rate
WO2005123040A1 (ja) * 2004-06-22 2005-12-29 Shionogi & Co., Ltd. 口腔内速崩壊錠

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020262618A1 (en) * 2019-06-28 2020-12-30 Ssp Co., Ltd. Meloxicam-containing granulated product
JP2021008412A (ja) * 2019-06-28 2021-01-28 エスエス製薬株式会社 メロキシカム含有造粒物
JP7348703B2 (ja) 2019-06-28 2023-09-21 エスエス製薬株式会社 メロキシカム含有造粒物
CN115093859A (zh) * 2022-05-05 2022-09-23 朱贵远 一种聚丙烯酸钠防溅制剂及其制备方法
CN115093859B (zh) * 2022-05-05 2024-03-01 朱贵远 一种聚丙烯酸钠防溅制剂及其制备方法

Also Published As

Publication number Publication date
CN101374503A (zh) 2009-02-25
KR20080108227A (ko) 2008-12-12
CN101374503B (zh) 2012-09-05
KR101386022B1 (ko) 2014-04-16
JP4965130B2 (ja) 2012-07-04
JP2007197357A (ja) 2007-08-09

Similar Documents

Publication Publication Date Title
JP4965130B2 (ja) 乾式直打速崩壊性錠剤
JP5296456B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
EP1539112A1 (en) Use of an aqueous solution of citric acid and a water-soluble sugar like lactitol as granulation liquid in the manufacture of tablets
EP2465495A1 (en) Tablet that disintegrates rapidly in the mouth and that contains two or more types of particles
JP5870690B2 (ja) 口腔内崩壊錠及びその製造方法
KR20040058189A (ko) 관능상 허용가능한 경구내 붕해 조성물
JP6919119B2 (ja) ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
JP5974469B2 (ja) 錠剤の製造方法
JP2017141299A (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP2010270110A (ja) ネオテームを含有する経口製剤
JP5870775B2 (ja) 錠剤及びその製造方法
JP2003176242A (ja) 速崩壊性圧縮成型物及びその製造法
JP3899522B2 (ja) 苦味が低減されたプランルカスト水和物を含有する製剤
JP2010241760A (ja) 不快な味の軽減された口腔内速崩壊錠及びその製造方法
TW201315462A (zh) 異丁苯丙酸可嚼錠
TWI468189B (zh) Oral internal disintegrating tablet and its manufacturing method
JPWO2010119851A1 (ja) 口腔内崩壊錠
JP2015110663A (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP7250305B2 (ja) メマンチン又はその薬物学的に許容される塩を含む医薬組成物及びその製造方法
JP6151413B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP5714652B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP2017052755A (ja) 固形製剤
JP3637968B1 (ja) 胃内崩壊性錠剤
US20240091367A1 (en) Orally disintegrating palatable formulations of drotaverine and method of preparation thereof
JP2021113237A (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 200780003393.X

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020087019484

Country of ref document: KR

122 Ep: pct application non-entry in european phase

Ref document number: 07707403

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)